Find a story
Search Spins
Search titles, summaries, and missing voices across published articles — press releases, announcements, and media coverage.
5 results for “Phase 3”
Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Primary Endpoints in First-Line PD-L1-High Metastatic NSCLC
A Phase 3 clinical trial (EVOKE-03/KEYNOTE-D46) testing sacituzumab govitecan plus pembrolizumab in first-line PD-L1-high metastatic NSCLC failed to meet its primary endpoints of progression-free survival and overall survival, though it showed numerically improved but statistically non-significant outcomes.
Sep 13, 2026
REGN 1-WEEK DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit
A securities class action lawsuit has been filed against Regeneron Pharmaceuticals following surprising revelations about a Phase 3 clinical trial of an undisclosed therapy, triggering investor alerts ahead of a September 14, 2026 lead plaintiff deadline.
Sep 7, 2026
Moderna stock, $MRNA , surges over +110% after announcing the first ever positive Phase 3 results for a personalized cancer vaccine.
Moderna and Merck announced positive Phase 3 trial results for a personalized mRNA cancer vaccine that reduced melanoma recurrence, triggering a >110% stock surge for Moderna.
Published Aug 19, 2026 · Analyzed Aug 21, 2026
Moderna reports first positive Phase 3 for mRNA neoantigen therapy in melanoma
A Hacker News thread titled 'Moderna reports first positive Phase 3 for mRNA neoantigen therapy in melanoma' contains only the word 'Comments' as its body — no factual reporting, data, source link, or attribution is provided.
Aug 19, 2026
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder - Business Wire
Vistagen reported topline and post-hoc results from PALISADE-4, a Phase 3 clinical trial evaluating fasedienol for acute treatment of social anxiety disorder using a public speaking challenge paradigm.
Published Jun 30, 2026 · Analyzed Jul 8, 2026